Trevi climbs as GSK drops chronic cough therapy (TRVI:NASDAQ)
· seekingalpha.com
Trevi Therapeutics (TRVI) stock jumps as GSK (GSK) discontinues a chronic cough therapy following a late-stage trial failure. Read more here.
After GSK (GSK) announced it would discontinue a chronic cough therapy following a late-stage trial failure, Trevi Therapeutics (TRVI), which is advancing a riv...